{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=17", "query": { "intervention": "B complex", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 912, "total_pages": 92, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B+complex&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T13:05:56.618Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01000974", "title": "Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)", "type": "BIOLOGICAL" }, { "name": "ActHIB™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "Pediarix™", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "Rotarix™", "type": "BIOLOGICAL" }, { "name": "Engerix™-B", "type": "BIOLOGICAL" }, { "name": "Infanrix™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 4003, "start_date": "2010-06-18", "completion_date": "2013-07-17", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 63, "location_summary": "Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000974" }, { "nct_id": "NCT04896086", "title": "First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Seasonal Influenza" ], "interventions": [ { "name": "VRC-GENADJ0110-AP-NV (Adjuplex)", "type": "DRUG" }, { "name": "Flucelvax", "type": "BIOLOGICAL" }, { "name": "VRC-FLUMOS0111-00-VP (FluMos-v1)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 63, "start_date": "2021-05-24", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04896086" }, { "nct_id": "NCT00621049", "title": "Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel/Carboplatin/Bevacizumab/Erlotinib", "type": "DRUG" }, { "name": "Docetaxel/Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2007-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 26, "location_summary": "Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00621049" }, { "nct_id": "NCT04322318", "title": "A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Kidney Wilms Tumor", "Recurrent Kidney Wilms Tumor", "Stage II Kidney Wilms Tumor", "Stage III Kidney Wilms Tumor", "Stage IV Kidney Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Surgical Procedure", "type": "PROCEDURE" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Transabdominal Ultrasound", "type": "PROCEDURE" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 256, "start_date": "2020-10-19", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 178, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04322318" }, { "nct_id": "NCT01803282", "title": "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Non-small Cell Lung Cancer", "Esophagogastric Cancer", "Colorectal Cancer", "Breast Cancer" ], "interventions": [ { "name": "Andecaliximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 236, "start_date": "2013-03-29", "completion_date": "2019-04-23", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01803282" }, { "nct_id": "NCT00794079", "title": "Omega-3 Fatty Acids and Muscle Protein Synthesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "omega-3 fatty acids", "type": "DIETARY_SUPPLEMENT" }, { "name": "corn oil", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 43, "start_date": "2007-06", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2011-08-03", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00794079" }, { "nct_id": "NCT01064479", "title": "Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Cell Carcinoma of the Hypopharynx", "Metastatic Squamous Cell Carcinoma of the Larynx", "Metastatic Squamous Cell Carcinoma of the Oral Cavity", "Metastatic Squamous Cell Carcinoma of the Oropharynx", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2010-02-05", "completion_date": "2020-11-03", "has_results": true, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 5, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064479" }, { "nct_id": "NCT03673462", "title": "Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Volunteers (Meningococcal Infection)" ], "interventions": [ { "name": "Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)", "type": "BIOLOGICAL" }, { "name": "Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)", "type": "BIOLOGICAL" }, { "name": "Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Rotavirus Vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, and Rubella Virus Vaccine", "type": "BIOLOGICAL" }, { "name": "Varicella Virus Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "42 Days to 89 Days" }, "enrollment_count": 2797, "start_date": "2018-09-17", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673462" }, { "nct_id": "NCT02214225", "title": "A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Quadrivalent Influenza Vaccine (QIV)", "type": "BIOLOGICAL" }, { "name": "Trivalent Influenza Vaccine (TIV-1)", "type": "BIOLOGICAL" }, { "name": "Trivalent Influenza Vaccine (TIV-2)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seqirus", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3484, "start_date": "2014-08", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 33, "location_summary": "Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Milford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214225" }, { "nct_id": "NCT02141581", "title": "Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Fluzone® (IM)", "type": "BIOLOGICAL" }, { "name": "Fluzone® Intradermal (ID)", "type": "BIOLOGICAL" }, { "name": "2011-2012 FluMist®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "8 Years to 34 Years" }, "enrollment_count": 86, "start_date": "2011-08", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-05-07", "last_synced_at": "2026-10-19T13:05:56.618Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02141581" } ] }